Vasomotor Symptoms (VMS): Pharmacological Management and Updates

Jayalath JAVS¹

¹ Acting Obstetrician and Gynaecologist, Base Hospital, Udugama, Sri Lanka.

Corresponding author – Dr Jayalath J.A.V.S.
Email: sharadajayalath@yahoo.com

https://orcid.org/0000-0003-4100-0384

Vasomotor symptoms

Hot flushes and night sweats are the most common symptoms seen in peri and postmenopausal women and known as vasomotor symptoms (VMS). Hot flushes originate as a sudden onset sensation of heat, arising from the neck and the central chest, and then rapidly generalized into the other parts of the body¹. Hot flushes are usually last for 1-5 minutes, but it can be last up to 15-60 minutes². The occurrence of hot flushes during sleep is termed night sweats¹. Other symptoms associated with VMS include headache, chest discomfort, nausea, anxiety, tachycardia, and tachypnoea.

VMS are common in postmenopausal women, though they can be appeared in perimenopausal period and rarely in premenopausal period³. It is evident that 60%-80% of postmenopausal women are experiencing VMS⁴,⁵. Median duration of occurrence of VMS is about 5.2 years⁶. 15%-20% of postmenopausal women experience VMS for longer duration (up to 15 years)⁷.

Pathophysiology

Despite extended research on occurrence of VMS, exact pathophysiology is not established yet. Currently, it is believed to be associated with reduction in estrogen levels during menopause, which is causing disturbances in thermoregulatory center in the brain⁷.

Core body temperature (CBT) homeostasis is regulated between the upper and the lower thresholds, which is called thermoregulatory zone or

Figure 01 - The differences of thermoregulation during pre/peri/postmenopausal periods
thermoneutral zone. Vasodilatation and sweating occur when the upper threshold (upper limit) of normal thermoregulatory zone is exceeded. Chills and rigors occur when the lower threshold (lower limit) of normal thermoregulatory zone is exceeded. Small changes in CBT are regulated by peripheral blood circulation.

Lower level of estrogen during peri and postmenopausal period is associated with narrowing of thermoregulatory zone in the hypothalamus due to several mechanisms. This causes frequent hot flushes and sweating due to minor changes in the core body temperature (Figure 01). However reduced estrogen level alone does not explain the occurrence of vasomotor symptoms.

Several hypotheses have been postulated to discuss the reduced estrogen levels causing narrowing of thermoregulatory zone. These hypotheses include,

1. Role of serotonin and endorphins
2. Role of hypothalamic Kisspeptin, Neurokinin-B and Dynorphin (KNDy) signalling system
3. Role of CGRP (Calcitonin Gene-Related Peptide)

During premenopausal period, estrogen stimulate the production of serotonin and endorphins, and there is a decreased serotonin level after menopause, corresponding to declining estrogen levels. Hypothalamic thermostat is disturbed by the reduced levels of serotonin and reflectively increased level of norepinephrine, resulting in narrowing of thermoregulatory zone.

Kisspeptin/Neurokinin-B/Dynorphin Neurones (KNDy Neurones), which is located in infundibular nucleus of hypothalamus, secrete Kisspeptin, Neurokinin-B and Dynorphin. Kisspeptin act on GnRH neurones stimulating the secretion of GnRH, which in turn stimulate the secretion of LH and FSH. Neurokinin-B and Dynorphin have a autoregulation mechanism on the KNDy neurones. Neurokinin-B act on median preoptic nucleus and thereby thermoregulatory center, increasing its sensitivity and narrowing the hypothalamic thermoregulatory Zone. Estrogen has a negative feedback on KNDy neurones. During menopause, lack of estrogen and its negative feedback on KNDy neurons cause increased Neurokinin-B signalling, resulted in narrowing of thermoregulatory zone causing VMS.

CGRP is a potent vasodilator seen in peripheral circulation. Serum CGRP levels are significantly higher in postmenopausal women who experienced VMS than premenopausal women. 24-hour urinary excretion of CGRP level is found to be higher in women who experienced VMS than who did not experience VMS. There are no differences of serum CGRP levels between premenopausal and postmenopausal women who did not experience VMS. Some studies have found an increased serum CGRP levels during the onset of hot flushes. These findings suggest that serum CGRP levels are regulated by serum estrogen level and reduction of serum estrogen level is associated with increased serum CGRP levels. The occurrence of VMS induced by CGRP may be mediated by increased peripheral vasodilatation following increased serum CGRP levels. However, exact association of serum CGRP levels with occurrence of VMS is yet to be studied.

**Effects of VMS**

VMS are negatively affected on work productivity, interpersonal relationships, sleep quality and overall quality of life in menopausal women. Persistent symptoms have caused increased healthcare resource utilization and increased healthcare related cost.

**Treatment options**

Treatment options of VMS include pharmacological therapies and complimentary therapies. Pharmacological therapies include Menopausal Hormone Therapy (MHT) and non-hormonal therapies like SSRIs, SNRIs and Gabapentinoids. Complementary therapies include herbal and nutrient supplements, lifestyle changes and mind body techniques. In addition, emerging therapies
include selective Neurokinin-3 (NK-3) receptor antagonists and dual Neurokinin-1 (NK-1) and Neurokinin-3 (NK-3) receptor antagonists.

Pharmacological therapies and emerging therapies are discussed in this review.

**Menopausal Hormone Therapy (MHT)**

MHT is the most effective standard treatment for VMS\(^ {17} \). Cochrane review of randomized control trials on MHT concluded that it is highly effective, with a 75% reduction of frequency and severity of VMS\(^ {18} \). Current recommendation is to start MHT within 10 years of menopause or under the age of 60 years (within window period).

However, MHT is associated with multiple adverse effects including venous thrombosis, transient ischaemic attacks, stroke, myocardial infarction, pulmonary embolism, and breast cancer\(^ {19} \). These systemic adverse effects can be minimized by local application of estrogen preparations by the means of transdermal estrogen patches, which has desirable serum estrogen concentration with small doses. Despite of the mode of administration, it is associated with increased risk of breast cancers, and in some patients MHT is contraindicated. Absolute contraindications of MHT include current breast cancer, current venous thromboembolism (VTE), active liver disease and SLE with renal involvement. History of breast cancer, history of VTE, migraine, epilepsy and other gynaecological cancers are considered as relative contraindications for MHT.

According to the newer evidence, MHT with combined equino estrogen (CEE) and medroxyprogesterone acetate (MPA) is not associated with increased risk of all cause, cardiovascular and cancer mortality for a median of 5.6 years\(^ {20} \). Further, MHT with CEE alone is not associated with increased risk of all cause, cardiovascular and cancer mortality for median of 7.2 years\(^ {20} \).

**Selective Serotonin Reuptake Inhibitors (SSRIs) and Serotonin–Norepinephrine Reuptake Inhibitors (SNRIs)**

SSRIs and SNRIs are non-hormonal pharmacological treatment options which are effective in reducing symptoms of VMS\(^ {21} \). Statistically significant reduction of VMS severity with SSRIs (Paroxetine, Citalopram and Escitalopram) and SNRIs (Venlafaxine and Desvenlafaxine) has been shown by large, randomized control trials (RCTs)\(^ {22} \). However, recent evidence has shown low dose estrogen therapy has superior efficacy than SSRIs and SNRIs\(^ {23} \).

SSRIs and SNRIs are contraindicated in patients with a history of neuroleptic syndrome or at risk of serotonin syndrome, and in patients who are using monoamine oxidase inhibitors concomitantly. Patients with liver or renal impairments, uncontrolled hypertension, and bipolar disorders, should be treated cautiously. Main side effects of SSRIs and SNRIs include nausea, fatigue, headache, dry mouth, and other gastrointestinal symptoms.

**Paroxetine**

Paroxetine mesylate 7.5 mg is the only non-hormonal pharmacological therapy approved by the United States Food and Drug Administration (US FDA) for treating moderate to severe vasomotor symptoms\(^ {24} \). Paroxetine mesylate 7.5mg or paroxetine hydrochloride 10-12.5 mg/day is recommended as the first line treatment option for VMS when MHT is not applicable\(^ {25} \).

Two phase III randomized clinical trials conducted in 2013 have found that paroxetine mesylate 7.5mg is effective in reduction of frequency and severity of moderate to severe VMS in postmenopausal women\(^ {26} \). This clinical trial had two study arms. Patients in both study arms were randomly given with paroxetine mesylate 7.5mg and a placebo at night for 12 weeks and 24 weeks respectively. Improvement of symptoms were assessed after 4 weeks and 12 weeks. In both studies, patients with paroxetine mesylate 7.5mg had report-
ed significantly reduced frequency and severity of VMS.

**Citalopram**

A phase III randomized clinical trial conducted in 2010 to evaluate the efficacy of citalopram in the management of VMS has found promising results (p < 0.002)\(^27\). Patients were randomly given citalopram 10mg/day, 20mg/day, 30mg/day and a placebo. Effects were assessed after 6 weeks, and 30mg/day group has recorded 55% reduction of VMS severity score, while 20mg/day group and 10mg/day groups have recorded 50% and 49% reduction compared to placebo (recorded as 23% reduction).

**Escitalopram**

A randomized double-blind placebo controlled clinical trial conducted in 2011 to evaluate the efficacy of escitalopram for VMS has concluded that escitalopram is significantly effective in reducing frequency (P < 0.001) and severity (P < 0.001) of VMS\(^28\). 205 postmenopausal women have participated in the study and the candidates were given with escitalopram 10mg/day, 20mg/day and a placebo and the effects were assessed in 8 weeks.

**Sertraline**

Sertraline has not shown consistent or significant improvements in severity or frequency of VMS and therefore it is not recommended for the treatment of VMS\(^29,30\).

**Fluoxetine**

Fluoxetine has not shown consistent or significant improvements in severity or frequency of VMS and therefore it is not recommended for the treatment of VMS\(^29,30\).

**Venlafaxine**

A study was done to evaluate the efficacy of 37.5mg, 75mg and 150mg Venlafaxine against a placebo\(^31\). It has found that 37.5mg dose had 37% reduction of VMS whereas 75mg and 150mg had 61% reduction of VMS. However, 150mg Venlafaxine has associated with significant side effects including dry mouth, decreased appetite, nausea, and constipation.

Venlafaxine is not superior to MHT, but it is a good option for treatment of VMS.

**Desvenlafaxine**

Desvenlafaxine is the major active metabolite of Venlafaxine. In animal studies, Desvenlafaxine significantly increased the secretion of serotonin and norepinephrine in the hypothalamus\(^32\).

Evidence has found that 100mg Desvenlafaxine or higher doses has significant reduction of frequency of moderate to severe VMS\(^33\). It also found that 100mg Desvenlafaxine is not associated with significant side effects. However, there is insufficient evidence to recommend it over other non-pharmacological treatments. Therefore, clinical trials comparing the efficacy of Desvenlafaxine compared to other nonhormonal treatments are needed to be established.

**Gabapentinoids**

**Gabapentin**

Gabapentin is a gamma-aminobutyric analogue, and the exact mechanism of alleviating VMS is still unclear. Studies has shown affinity of gabapentin for calcium channels in the hypothalamus, widening the thermoregulatory zone, resulting in the reduction of hot flushes\(^34,35\).

Recent evidence has shown favorable effects of gabapentin in relieving VMS compared to controls\(^36\). A meta-analysis has shown that reduction in severity and frequency of VMS were between 20%-30% and the doses used to treat VMS were between 900-2400mg\(^37\). However, the effect is less superior than those of estrogen\(^36\). When compared to SSRIs and SNRIs, gabapentin showed equal efficacy in alleviating hot flushes\(^38\).
Major side effects of gabapentin include dizziness and somnolence. The recommended starting dose is 100mg/day and dose can be increased up to 900mg/day (three divided doses). These side effects can be reduced by starting with lower dose and gradually increasing and by prescribing the drugs at bedtime.

**Clonidine**

Clonidine is an alpha-2 adrenergic agonist and the mechanism of action of alleviating hot flushes is postulated as widening of thermoregulatory zone by reducing norepinephrine levels\(^1\). Its effects are modest compared to placebo but inferior to SSRIs, SNRIs and Gabapentinoids\(^{11,22,39}\). Few placebo-controlled trials has shown a reduction of severity of VMS over placebo but significant reduction of frequency of VMS has not shown\(^{40,41}\).

Clonidine is a less preferable option due to its side effects profile, which includes hypotension, light headedness, dry mouth, and dizziness.

**Pregabalin**

Pregabalin is a Gabapentinoid, and it is used as an anticonvulsant and anxiolytic agent used to treat generalized anxiety disorder, epilepsy, fibromyalgia, restless leg syndrome, neuropathic pain, and opioid withdrawal.

A three-arm, double-blinded, placebo-controlled randomized trial was done in 2009 to assess the effectiveness of Pregabalin in the management of VMS\(^{42}\). Pregabalin, 75 mg twice a day, shown to be effective in the reduction of median score (severity and frequency) of VMS by 60% compared to placebo (50%)\(^{42}\). There was a 65% reduction with the dose of 150mg. But higher doses of Pregabalin is associated with more side effects and it is no more effective than lower doses. Side effects of Pregabalin includes changes in coordination, sleepiness, concentration difficulties, and visual changes.

However, the treatment of Pregabalin in the management of VMS is still inconclusive.

**Oxybutynin**

Oxybutynin has anticholinergic effects which has shown to be effective in the reduction of VMS. Recent RCT done in 2016 has found that Oxybutynin is an effective, nonhormonal therapy for moderate to severe VMS in postmenopausal women\(^{43}\). 73% of women had statistically significant symptom improvement compared to 26.1% in placebo group. In addition, women treated with Oxybutynin showed significant improvement in sleep quality, sleep disturbance, and the global sleep index. 52.1% participants had reported dry mouth and 6.8% of the participants had discontinued the treatment. However, current evidence is still not conclusive to recommend Oxybutynin for the treatment of VMS.

Oxybutynin should be used with caution in elderly women who have multiple comorbidities or polypharmacy due to drug interactions.

**Emerging Therapies: Neurokinin-B Antagonist**

Recent evidence has found that Neurokinin-B (NK-B) involved in the pathophysiology of VMS\(^{12}\). NK-B has the affinity to Neurokinin-3 (NK-3) receptors located on median preoptic nucleus and thereby thermoregulatory center resulted in narrowing of thermoregulatory zone. During postmenopausal period, lack of estrogen causes increased secretion of NK-B, overstimulating its action, resulted in VMS. Studies have been done on NK-B antagonists to assess the efficacy of its use in the treatment of VMS. NK-B antagonists are divided in to two categories as selective NK-3 antagonists and dual NK-1 and NK-3 receptor antagonists\(^{44}\).

**Fezolinetant**

Fezolinetant is a NK-3 receptor antagonist and is currently under clinical trials. Fezolinetant act by binding to NK-3 receptor and inhibiting the action of NK-B.
A phase 2-a randomized clinical trial was conducted in 2019 to assess the efficacy of Fezolinetant 90mg compared to placebo, in the treatment of VMS45. One arm was given with Fezolinetant 90mg two times a day for 12 weeks and the second arm was given a placebo. First arm, who was treated with Fezolinetant, had significant reduction of severity and frequency of moderate to severe VMS and there was a 74%-87% reduction of frequency of VMS compared to 55% reduction with a placebo46.

Common side effects of Fezolinetant include headache, fatigue, nausea, diarrhoea, sinusitis, and cough. Rare but serious side effects include retinal detachment, cholelithiasis, elevated liver function values, and adjustment disorders.

**Elinzanetant (NT-814)**

Elinzanetant (NT-814) is a dual NK-1 and NK-3 antagonist and still under clinical trials. A placebo-controlled, randomized clinical trial done in 2020 found that Elinzanetant 150mg has shown a greater reduction (84%) of frequency of VMS compared to other treatment doses (24% with 50mg, 100mg and 300mg) and placebos (37%)44. Another randomized, double-blind, placebo-controlled, dose-finding study done in 2020 found that 120mg and 160mg of Elinzanetant has shown the greatest mean reduction of VMS compared to lesser doses of 40mg and 80mg47. It also has shown statistically significant reduction of mood and sleep disorders47.

**Summary**

VMS symptoms are bothersome and affecting 60-80% postmenopausal women and median duration of VMS is 5.2 years. Exact pathophysiology of VMS is not established yet and currently, it is believed to be associated with reduction in estrogen levels causing disturbances in thermoregulatory center during menopause. Treatment options of VMS includes MHT, non-hormonal options and complimentary therapies. MHT considered to be the standard treatment option with 75% efficacy. Paroxetine mesylate 7.5 mg is the only non-hormonal pharmacological therapy approved by US FDA for treating moderate to severe vasomotor symptoms. Newer, emerging therapies, such as neurokinin 3 receptor antagonists and dual Neurokinin 1 and 3 receptor antagonists show promising effects in reduction of vasomotor symptoms.

**Author declarations**

Conflicts of interest: No conflicts of interest.
| Group                              | Drug          | Dose                | Evidence                                                                 | Recommendation                                                                 |
|------------------------------------|---------------|---------------------|--------------------------------------------------------------------------|------------------------------------------------------------------------------|
| MHT – Estrogens and Progestogens   | MHT           |                     | • Most effective standard treatment for VMS                               | Recommended Start within 10 years of menopause or under the age of 60 years  |
| Gabapentinoids                     | Gabapentin    | 100 - 900mg/day     | • Has shown that reduction in severity and frequency of VMS              | Can be recommended                                                           |
|                                    | Clonidine     | Patch - 0.1-0.3mg/week | • Effects are modest compared to placebos but inferior to SSRIs, SNRIs and Gabapentinoids | Can be recommended but it is a less preferable option due to its side effect profile |
|                                    | Pregabalin    | –                   | • Shown to be effective in the reduction of median score (severity and frequency) of VMS has not shown   | Inconclusive evidence to recommend                                             |
|                                    | Oxybutynin    | –                   | • Has shown improvements in hot flush frequency and severity             | Inconclusive evidence to recommend                                             |
| SSRI                               | Paroxetine    | 7.5-12.5mg/day      | • Statistically significant reduction of VMS severity but less superior than estrogen | Only non-hormonal pharmacological therapy Recommended by the US FDA           |
|                                    | Fluoxetine    | –                   | • Not shown consistent or significant improvements in VMS               | Not recommended                                                               |
|                                    | Sertraline    | –                   | • Not shown consistent or significant improvements in VMS               | Not recommended                                                               |
|                                    | Citalopram    | 10-20mg/day         | • Statistically significant reduction of VMS severity but less superior than estrogen | Can be recommended                                                           |
|                                    | Escitalopram  | 10-20mg/day         | • Statistically significant reduction of VMS severity but less superior than estrogen | Can be recommended                                                           |
| SNRI                               | Venlafaxine   | 37.5-75mg/day       | • Statistically significant reduction of VMS severity but less superior than estrogen | Can be recommended                                                           |
|                                    | Desvenlafaxine| 75-100mg/day        | • Has significant reduction of frequency of moderate to severe VMS      | Can be recommended but insufficient evidence to recommend over the other non-pharmacological methods |
|                                    | Selective NK-3 Antagonists | Fezolinetant | 90 mg/day | • Significant reduction (74%-87%) of severity and frequency of moderate to severe VMS | Still under clinical trials (Phase 2-a)                                      |
|                                    | Dual NK-1 and NK-3 Antagonists | Elinzanetant | 120-160 mg/day | • I20mg and 160mg has shown mean reduction of VMS | Still under clinical trials (Phase 3)                                        |

Table 01 - Pharmacological Management of VMS – Summary Table

References
1. Rebar RW, Spitzer IB. The physiology and measurement of hot flushes. American Journal of Obstetrics and Gynecology. 1987; 156(5):1284-12888. Doi: https://doi.org/10.1016/0002-9378(87)90165-7
2. Kronenberg F. Hot flashes: epidemiology and physiology. Annals of the New York Academy of Sciences. 1990; 592:52–86. Doi: https://doi.org/10.1111/j.1749-6632.1990.tb30316.x
3. Hahn PM, Wong J, Reid RL. Menopausal-like hot flashes reported in women of re-
productive age. Fertility and Sterility. 1998; 70:913–918. Doi: https://doi.org/10.1016/s0015-0282(98)00281-7

4. Freeman EW, Sherif K. Prevalence of hot flushes and night sweats around the world: a systematic review. Climacteric. 2007; 10:197–214. Doi: https://doi.org/10.1080/13697130601181486

5. Thurston RC, Joffe H. Vasomotor symptoms and menopause: findings from the Study of Women’s Health Across the Nation. Obstetrics and gynecology clinics of North America. 2011; 38(3):489–501. Doi: https://doi.org/10.1016/j.occ.2011.05.006

6. Crawford SL. The roles of biologic and non-biologic factors in cultural differences in vasomotor symptoms measured by surveys. Menopause 2007; 14:725–733. Doi: https://doi.org/10.1097/gme.0b013e31802efbb2

7. Freedman RR. Hot flashes: behavioral treatments, mechanisms, and relation to sleep. American Journal of Medicine 2005; 118:124S–130S. Doi: https://doi.org/10.1016/j.amjmed.2005.09.046

8. Savage MV, Brengelmann GL. Control of skin blood flow in the neutral zone of human body temperature regulation. Journal of applied physiology. 1996; 80:1249–1257. Doi: https://doi.org/10.1152/jappl.1996.80.4.1249

9. Freedman RR, Norton D, Woodward S, Cornelissen G. Core body temperature and circadian rhythm of hot flashes in menopausal women. The Journal of clinical endocrinology and metabolism. 1995; 80:2354–2358. Doi: https://doi.org/10.1210/jcem.80.8.7629229

10. Askel S, Schomberg DW, Tyrey L, Hammond CB. Vasomotor symptoms, serum estrogens, gonadotropin levels in surgical menopause. American journal of obstetrics and gynecology. 1976; 126:165–169. Doi: https://doi.org/10.1016/0002-9378(76)90270-2

11. Freedman RR. Menopausal hot flashes: mechanisms, endocrinology, treatment. The Journal of steroid biochemistry and molecular biology. 2014; 142:115-120. Doi: https://doi.org/10.1016%2Fj.jsbmb.2013.08.010

12. Rance NE, Dacks PA, Mittelman-Smith MA, et al. Modulation of body temperature and LH secretion by hypothalamic KNDy (kispeptin, neurokinin B and dynorphin) neurons: a novel hypothesis on the mechanism of hot flushes. Frontiers in neuroendocrinology. 2013; 34:211–27. Doi: https://doi.org/10.1016/j.j yerne.2013.07.003

13. Gupta P, Harte A, Sturdee DW, Sharma A, Barnett AH, Kumar S, McTernan PG. Effects of menopausal status on circulating calcitonin gene-related peptide and adipokines: implications for insulin resistance and cardiovascular risks. Climacteric. 2008; 11(5):364-367. Doi: https://doi.org/10.1080/13697130802378493

14. Wyon YA, Frisk J, Lundeberg T, Theodorsson E, Hammar M. Postmenopausal women with vasomotor symptoms have increased urinary excretion of calcitonin gene-related peptide. Maturitas. 1998; 30:289–294. Doi: https://doi.org/10.1016/s0378-5122(98)00047-4

15. Wyon YA, Spetz AC, Theodorsson GE, Hammar ML. Concentrations of calcitonin gene-related peptide and neuro-peptide Y in plasma increase during flushes in postmenopausal women. Menopause. 2000; 7(1):25-30. Doi: https://doi.org/10.1097/00042192-200007010-00005

16. Noguchi M, Ikarashi Y, Yuzurihara M, Mizoguchi K, Kurauchi K, Chen J, Ishige A, Up-regulation of calcitonin gene-re-
lated peptide receptors underlying elevation of skin temperature in ovariectomized rats. The Journal of endocrinology. 2002; 175:177–183. Doi: https://doi.org/10.1677/joe.0.1750177

17. Hedrick RE, Ackerman RT, Kolrun WD, et al. Transdermal estradiol gel 0.1% for the treatment of vasomotor symptoms in postmenopausal women. Menopause. 2009; 16:132–140. https://doi.org/10.1097/gme.0b013e31817d3372

18. Maclennan AH, Broadbent JL, Lester S, Moore V. Oral estrogen and combined estrogen/progestogen therapy versus placebo for hot flushes. Cochrane Database Syst Rev. 2004; 18:2004(4):CD002978. Doi: https://doi.org/10.1002/14651858.cd002978.pub2

19. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the women’s health initiative randomized controlled trial. JAMA. 2002; 288:321–333. Doi: https://doi.org/10.1001/jama.288.3.321

20. Manson JAE, Aragaki AK, Rossouw JE, Anderson GL, et al. Menopausal Hormone Therapy and Long-term All-Cause and Cause-Specific Mortality: The Women’s Health Initiative Randomized Trials. JAMA. 2017; 318(10):927-938. Doi: https://doi.org/10.1001/jama.2017.11217

21. Gordon PR, Kerwin JP, Boesen KG, et al. Sertraline to treat hot flashes: a randomized controlled, double-blind, crossover trial in a general population. Menopause. 2006; 13:568–575. Doi: https://doi.org/10.1097/gme.0b013e3182a66aa7

22. Nonhormonal management of menopause-associated vasomotor symptoms: 2015 position statement of The North American Menopause Society. Menopause. 2015; 22:115–172. Doi: https://doi.org/10.1097/gme.0000000000000546

23. Joffe H, Guthrie KA, LaCroix AZ, et al. Low-dose estradiol and the serotonin-norepinephrine reuptake inhibitor venlafaxine for vasomotor symptoms. JAMA internal medicine. 2014; 174:1058-1066. Doi: https://doi.org/10.1001/jama.2014.1891

24. Orleans RJ, Li L, Kim MJ, et al. FDA approval of paroxetine for menopausal hot flushes. The New England Journal of Medicine. 2014; 370:1777–1779. Doi: https://doi.org/10.1056/nejmp1402080

25. Carroll DG, Lisenby KM, Carter TL. Critical appraisal of paroxetine for the treatment of vasomotor symptoms. International journal of women’s health. 2015; 7:615–624. Published online 2015 Jun 18. Doi: https://doi.org/10.2147/ijwh.s50804

26. Simon JA, Portman DJ, Kaufman AM, et al. Low-dose paroxetine 7.5 mg for menopausal vasomotor symptoms: two randomized controlled trials. Menopause. 2013; 20(10):1027–1035. Doi: https://doi.org/10.1097/gme.0b013e3182a66aa7

27. Barton DL, LaVasseur B, Sloan JA, et al. A phase III trial evaluating three doses of citalopram for hot flashes: NCCTG trial N05C9. Journal of clinical oncology. 2010; 28(20):3278–3283. Doi: https://doi.org/10.1200%2FJCO.2009.26.6379

28. Freeman EW, Guthrie KA, Caan B, et al. Efficacy of escitalopram for hot flashes in healthy menopausal women: a randomized controlled trial. JAMA. 2011; 305:267. Doi: https://doi.org/10.1001/jama.2010.2016

29. Grady D, Cohen B, Tice J, et al. Inefficacy of sertraline for treatment of menopaus-
30. Loprinzi CL, Sloan JA, Perez EA. et al. Phase III evaluation of fluoxetine for treatment of hot flashes. Journal of clinical oncology. 2002; 20:1578–1583. Doi: https://doi.org/10.1200/jco.2002.20.6.1578

31. Loprinzi CL, Kugler JW, Sloan JA, et al. Venlafaxine in management of hot flashes in survivors of breast cancer: a randomized controlled trial. Lancet. 2000; 356(9247):2059–2063. Doi: https://doi.org/10.1016/s0140-6736(00)03403-6

32. Deecher DC, Alfinito PD, Leventhal L. Alleviation of thermoregulatory dysfunction with the new serotonin and norepinephrine reuptake inhibitor desvenlafaxine succinate in ovariectomized rodent models. Endocrinology. 2007; 148(3):1376–1383. Doi: https://doi.org/10.1210/en.2006-1163

33. Umland EM, Falconieri L. Treatment options for vasomotor symptoms in menopause: focus on desvenlafaxine. International journal of women’s health. 2012; 4:305–319. Doi: https://doi.org/10.2147%2FIJWH.S24614

34. Yoon SH, Lee JY, Lee C, et al. Gabapentin for the treatment of hot flushes in menopause: a meta-analysis. Menopause. 2020; 27:485–493. Doi: https://doi.org/10.1097/gme.0000000000001491

35. Guttuso T, Kurlan R, McDermott MP, Kieburtz K. Gabapentin’s effects on hot flashes in postmenopausal women: a randomized controlled trial. Obstetrics and gynecology. 2003; 101:337–345. Doi: https://doi.org/10.1016/s0029-7844(02)02712-6

36. Shan D, Zou L, Liu X, Shen Y, Cai Y, Zhang J. Efficacy and safety of gabapentin and pregabalin in patients with vasomotor symptoms: a systematic review and meta-analysis. American journal of obstetrics and gynecology 2020; 222(6):564-579. Doi: https://doi.org/10.1016/j.ajog.2019.12.011

37. Butt DA, Lock M, Lewis JE, Ross S, Moineddin R. Gabapentin for the treatment of menopausal hot flashes: a randomized controlled trial. Menopause 2008; 15:310–318. Doi: https://doi.org/10.1097/gme.0b013e3180dca175

38. Guttuso TJ. Gabapentin’s effects on hot flashes and hypothermia. Neurology. 2000; 54:2161–2163. Doi: https://doi.org/10.1212/wnl.54.11.2161

39. Laufer LR, Erlik Y, Meldrum DR, Judd HL. Effect of clonidine on hot flashes in postmenopausal women. Obstetrics and gynecology 1982; 60:583–586.

40. Pandya KJ, Raubertas RF, Flynn PJ, Hynes HE, Rosenbluth RJ, Kirshner JJ, et al. Oral clonidine in postmenopausal patients with breast cancer experiencing tamoxifen-induced hot flashes: a University of Rochester Cancer Center Community Clinical Oncology Program study. Annals of internal medicine 2000; 132:788–793. Doi: https://doi.org/10.7326/0003-4819-132-10-200005160-00004

41. Goldberg RM, Loprinzi CL, O’Fallon JR, Veeder MH, Miser AW, Mailliard JA, et al. Transdermal clonidine for ameliorating tamoxifen-induced hot flashes. Journal of clinical oncology 1994; 12:155–158. Doi: https://doi.org/10.1200/jco.1994.12.1.155

42. Loprinzi CL, Qin R, Stella PJ, Rowland KM, Graham DL, ErwinS N, Dakhil R, D. Jurgens DJ, Burger KN. Pregabalin for hot flashes
in women: NCCTG trial N07C1. Journal of Clinical Oncology 2009; 27(15). Doi: https://doi.org/10.1200/jco.2009.27.15_suppl.951

43. Simon JA, Gaines T, LaGuardia KD, Extended-Release Oxybutynin Therapy for VMS Study Group. Extended-release oxybutynin therapy for vasomotor symptoms in women: a randomized clinical trial, Randomized Controlled Trial. Menopause 2016; 23(11):1214-1221. Doi: https://doi.org/10.1097/gme.0000000000000773

44. Trower M, Anderson RA, Ballantyne E, et al. Effects of NT-814, a dual neurokinin 1 and 3 receptor antagonist, on vasomotor symptoms in postmenopausal women: a placebo-controlled, randomized trial. Menopause. 2020; 27:498–505. Doi: https://doi.org/10.1097/gme.000000000000150

45. Depypere H, Timmerman D, Donders G, et al. Treatment of menopausal vasomotor symptoms with fezolinetant, a neurokinin 3 receptor antagonist: a phase 2a trial. The Journal of clinical endocrinology and metabolism 2019; 104:5893–5905. Doi: https://doi.org/10.1210/jc.2019-00677

46. Fraser GL, Lederman S, Waldbaum A, et al. A phase 2b, randomized, placebo-controlled, double-blind, dose-ranging study of the neurokinin 3 receptor antagonist Fezolinetant for vasomotor symptoms associated with menopause. Menopause. 2020; 27:389–392. Doi: https://doi.org/10.1097/gme.0000000000001510

47. Simon J, Anderson RA, Ballantyne E, et al. OR11-03 NT-814, a non-hormonal dual neurokinin 1,3 receptor antagonist markedly improves vasomotor symptoms in post-menopausal women: results of a randomized, double-blind, placebo-controlled dose-finding study (SWITCH-1). Journal of the Endocrine Society. 2020; 4(Suppl. 1): OR11–03. Doi: https://doi.org/10.1210%2Fjendso%2Fbva046.2071